Examining correlations between pharmaceutical nonadherence and 30-day hospital readmissions
RightCare is a medical technology company located in Horsham, Pennsylvania, that provides hospitals and health systems a comprehensive, end-to-end software application comprised of 3 modules—RightCare Risk Assessment, RightCare Coordination Central, and RightCare Post Care Connect—designed to assess patient risk at the time of admission, ensure the appropriate care plan is offered, and seamlessly transition patient information to post-acute care providers. RightCare’s software, based on 10 years of academic and clinical research, has been proven to reduce readmission rates by as much as 35%.
Hospital readmissions is a staggering issue currently placing significant financial strain on the healthcare system in the United States, contributing upward of $30 billion in annual costs. With nearly 1 in 5 Medicare patients returning to the hospital within 30 days, many institutions are seeking a solution. To address the severity of this issue, the 2010 Affordable Care Act established the Hospital Readmission Reduction Program in order to penalize hospitals with excessive readmission rates through reduced inpatient prospective payment system (IPPS) payments. This reduction in IPPS payments to such hospitals with excess readmissions was effective beginning October 1, 2012. In 2013, 2225 hospitals were penalized and lost up to 2% of their Medicare reimbursement.
A number of various factors contribute to patient readmissions; however, pharmaceutical nonadherence in particular plays a major role. Like hospital readmissions, nonadherence costs the US healthcare system billions in avoidable spending annually. This $300 billion issue results in lost business for pharmaceutical companies, increased emergency room visits, and now penalties for not achieving optimal patient outcomes.